Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery


ISSN (Print): 1574-8928
ISSN (Online): 2212-3970

Review Article

Recent Patents on the Development of c-Met Kinase Inhibitors

Author(s): Xiangming Xu and Lei Yao*

Volume 15, Issue 3, 2020

Page: [228 - 238] Pages: 11

DOI: 10.2174/1574892815666200630102344

Price: $65


Background: Receptor Tyrosine Kinases (RTKs) play critical roles in a variety of cellular processes including growth, differentiation and angiogenesis, and in the development and progression of many types of cancer. Mesenchymal-Epithelial Transition Factor (c-Met) kinase is one of the types of RTKs and has become an attractive target for anti-tumor drug designing. c-Met inhibitors have a broad prospect in tumor prevention, chemotherapy, biotherapy, and especially in tumor resistance.

Objective: The purpose of this article is to review recent research progress of c-Met inhibitors reported in patents since 2015.

Methods: A comprehensive Scifinder and Web of Science literature review was conducted to identify all c-Met inhibitors published in patents since 2015.

Results: There are two kinds of c-Met inhibitors, one is from natural products, and the other one is of synthetic origin. Most of these c-Met inhibitors show potent in vivo and in vitro antitumor activities and have potential in the treatment of cancers.

Conclusion: c-Met kinase inhibitors have emerged as an exciting new drug class for the treatment of all kinds of cancers, especially the Non-Small Cell Lung Cancer (NSCLC) with tumor resistance. More studies should be conducted on natural products to find novel c-Met kinase inhibitors.

Keywords: Cancer, c-Met, inhibitors, patent, progress, receptor tyrosine kinases.

Butti R, Das S, Gunasekaran VP, Yadav AS, Kumar D, Kundu GC. Receptor tyrosine kinases (RTKs) in breast cancer: Signaling, therapeutic implications and challenges. Mol Cancer 2018; 17(1): 34.
[] [PMID: 29455658]
Tomiguchi M, Yamamoto Y, Yamamoto-Ibusuki M, et al. Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer. Cancer Sci 2016; 107(4): 491-8.
[] [PMID: 26801869]
Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2010; 141(7): 1117-34.
[] [PMID: 20602996]
Baldacci S, Kherrouche Z, Cockenpot V, et al. MET amplification increases the metastatic spread of EGFR-mutated NSCLC. Lung Cancer 2018; 125: 57-67.
[] [PMID: 30429039]
Tsakonas G, Botling J, Micke P, et al. c-MET as a biomarker in patients with surgically resected non-small cell lung cancer. Lung Cancer 2019; 133: 69-74.
[] [PMID: 31200831]
Ma PC, Maulik G, Christensen J, Salgia R. c-Met: Structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003; 22(4): 309-25.
[] [PMID: 12884908]
Xing W, Ai J, Jin S, et al. Enhancing the cellular anti-proliferation activity of pyridazinones as c-met inhibitors using docking analysis. Eur J Med Chem 2015; 95: 302-12.
[] [PMID: 25827399]
Parikh PK, Ghate MD. Recent advances in the discovery of small molecule c-Met kinase inhibitors. Eur J Med Chem 2018; 143: 1103-38.
[] [PMID: 29157685]
Toiyama Y, Miki C, Inoue Y, Okugawa Y, Tanaka K, Kusunoki M. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients. Int J Cancer 2009; 125(7): 1657-62.
[] [PMID: 19569242]
Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009; 27(10): 1667-74.
[] [PMID: 19255323]
Wu ZX, Yang Y, Teng QX, et al. Tivantinib, A c-Met inhibitor in clinical trials, is susceptible to ABCG2-mediated drug resistance. Cancers (Basel) 2020; 12(1): 186.
[] [PMID: 31940916]
Adjei AA, Sosman JA, Martell RE, et al. Efficacy in selected tumor types in a phase I study of the c-Met inhibitor ARQ 197 in combination with sorafenib. J Clinical Oncology 2011; 29(15_suppl): 3034.
Kim HJ, Yoon A, Ryu JY, et al. c-Met as a potential therapeutic target in ovarian clear cell carcinoma. Sci Rep 2016; 6: 38502.
[] [PMID: 27917934]
Kim NA, Hong S, Kim KH, et al. New preclinical development of a c-Met inhibitor and its combined anti-tumor effect in c-Met-Amplified NSCLC. Pharmaceutics 2020; 12(2): 121.
[] [PMID: 32028611]
An S, Yu J, Xu T, Hao P. Application of dictamnine in preparation of c-Met inhibitor for treating cancer. CN110755435, 2020.
Aliebrahimi S, Kouhsari SM, Arab SS, Shadboorestan A, Ostad SN. Phytochemicals, withaferin A and carnosol, overcome pancreatic cancer stem cells as c-Met inhibitors. Biomed Pharmacother 2018; 106: 1527-36.
[] [PMID: 30119228]
Al-Salama ZT, Keating GM. Cabozantinib: A review in advanced renal cell carcinoma. Drugs 2016; 76(18): 1771-8.
[] [PMID: 27909994]
Sahu A, Prabhash K, Noronha V, Joshi A, Desai S. Crizotinib: A comprehensive review. South Asian J Cancer 2013; 2(2): 91-7.
[] [PMID: 24455567]
Duan M, Liu J, Tian S, Deng W, Yan C, Zhao L. Preparation of the multi-substituted pyridone derivatives and medical applications. WO2020042618, 2020.
Duan M, Liu J, Tian S, Dai Q, Xiong Y. Polysubstituted pyridonederivative useful in treatment of cancer and its preparation. WO2019080723, 2019.
Xu X, Li G, Ding C- Z, et al. Pyridone compound as c-Met inhibitor. WO2018077227, 2018.
Xu X, Li G, Yao T, Wang K, Hu L, Ding CZ. Crystal form of c-Met inhibitor and salt form thereof and preparation method therefor. WO2019206268, 2019.
Srivastava SK, Jha A, Agarwal SK, Mukherjee R, Burman AC. Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Anticancer Agents Med Chem 2007; 7(6): 685-709.
[] [PMID: 18045063]
Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, et al. Foretinib is a potent ROS1 inhibitor. Proc Natl Acad Sci USA 2013; 110(48): 19519-24.
[] [PMID: 24218589]
Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 2015; 21(18): 5445-53.
[] [PMID: 25987766]
Chen G. Compounds as c-Met kinase inhibitors. WO2012034055, 2012.
Gong F, Huang T, Zang H, Zhang S, Zhao R, Liu F. Preparation of N-[4-[[7-[[1-(cyclopentylamino)cyclopropyl]methoxy]-6- methoxy-4-quinolinyl oxy]-3-fluorophenyl]-N'-(4-fluorophenyl)-1,1-cyclopropanedicarboxamide crystal as c-Met kinase inhibitor for treatment of cancer. WO2019166012, 2019.
Zhang Q, Yu S, Wang Z, et al. Dioxazoline compound, preparation method therefor, and uses thereof. WO2019154133, 2019.
Zhang Q, Zhang H, Yang L, et al. Dioxanoquinazoline, dioxanoquinazoline-type compound, preparation method and application. WO2018153293, 2018.
Nan X, Li HJ, Fang SB, Li QY, Wu YC. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions. Eur J Med Chem 2020; 193: 112241.
[] [PMID: 32200199]
Zhang QW, Ye ZD, Shen C, Tie HX, Wang L, Shi L. Synthesis of novel 6,7-dimethoxy-4-anilinoquinolines as potent c-Met inhibitors. J Enzyme Inhib Med Chem 2019; 34(1): 124-33.
[] [PMID: 30422010]
Zhao Z, Wang H, Wu C. [1,2,4] triazol [4,3-a] pyridine derivate preparation method therefor or medical application thereof. WO2014180182, 2014.
Li X, Zhang L, Sun Q, Lv A. Crystalline free base of C-MET inhibitor or crystalline acid salts, preparation methods and application. WO2016015653, 2016.
Yang B, Zhu Q, Pan B. Method for preparing c-Met tyrosine kinase inhibitor. CN106883250, 2017.
Yang B, Zhu Q, Pan B. Method for preparing c-Met tyrosine kinase inhibitor. WO2017101885, 2017.
Brown N. Bioisosteres in Medicinal Chemistry. 1st ed. Wiley-VCH. 2012
Zhang Y, Chen Z, Wang Y, et al. Preparation of the azaindole derivative and their application as the c-Met inhibitor for the treatment of cancer. WO2020015744, 2020.
Hinklin RJ, Allen S, Barbour P, et al. Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases and their preparation. WO2020047184, 2020.
Zheng P, Zhu W, Tang Q, et al. Preparation of antitumor pyrrolopyrimidines. CN107383016, 2017.
Zhu W, Zheng P, Wang L, et al. Thienopyrimidine compound containing heteroaryl amide structure useful in treatment of cancer and its preparation. CN107253964, 2017.
Wang L, Liu X, Duan Y, et al. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Chem Biol Drug Des 2018; 92(1): 1301-14.
[] [PMID: 29575727]
Li J, Gu W, Bi X, et al. Design, synthesis, and biological evaluation of thieno[2,3-d]pyrimidine derivatives as novel dual c-Met and VEGFR-2 kinase inhibitors. Bioorg Med Chem 2017; 25(24): 6674-9.
[] [PMID: 29146452]
Zhao G, Zhao Y, Hu Y. Preparation of the indole-based small molecule C-MET inhibitor applied to treatment of cancers. CN107311983, 2017.
Zhao G, Hou Y, Zhao Y. Method for preparing indole type c-Met inhibitor. CN107382968, 2017.
Tang Q, Zheng P, Zhu W, et al. 1-Aryl-4-oxy-1,4-dihydroquinoline structure of pyridine and heterocyclic compound, preparation method and its application. CN108948014, 2018.
Sharma S, Zeng JY, Zhuang CM, et al. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol Cancer Ther 2013; 12(5): 725-36.
[] [PMID: 23468529]
Li X, Li D, Hong R. Preparation of c-Met inhibitor as anti-cancer drug. CN110218191, 2019.
Liu L, Siegmund A, Xi N, et al. Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458). J Med Chem 2008; 51(13): 3688-91.
[] [PMID: 18553959]
Huang W, Qian H, Gu W. Preparation of the 2,4-disubstituted pyridine and their medicine application for the treatment of cancer. CN108069938, 2018.
Li Q, Hu L, Dong H, et al. 3-(4-Fluorophenyl pyrimidone)-5-carboxamide derivative useful in treatment of cancer and its preparation. CN106543145, 2017.
Li Y, Geng M, Cui H, Ai J, Zhang W, Peng X. Quinolinones compound, preparation method, and use thereof. CN106146464, 2016.
Zagni C, Floresta G, Monciino G, Rescifina A. The search for potent, small-molecule HDACIs in cancer treatment: A decade after vorinostat. Med Res Rev 2017; 37(6): 1373-428.
[] [PMID: 28181261]
Unknown. c-Met/HDAC double-target inhibitor based on crizotinib structure and synthesis method for antitumor drug. CN110003181, 2019.
Unknown. c-Met/HDAC double-target inhibitor, its synthesis method and application in preparing antitumor drugs. CN110128411, 2019.
Unknown. Novel c-Met/HDAC dual-target inhibitor and its synthesis method for antitumor drug preparation. CN110016013, 2019.
Cai P, Wang B. Preparation of 2,4-disubstituted triazole compounds with ALK and c-Met inhibition activities. CN105348265, 2016.
Xiong H, Cheng J, Zhang J, et al. Design, synthesis, and biological evaluation of pyridineamide derivatives containing a 1,2,3-triazole fragment as type II c-Met inhibitors. Molecules 2019; 25(1): 10.
[] [PMID: 31861448]
Wang L, Gao M, Tong M, et al. Pharmacologic characterization of CT-711, a novel dual inhibitor of ALK and c-Met. Am J Cancer Res 2018; 8(8): 1541-50.
[PMID: 30210922]
Hao H, Huang X, Tam A, Kasibhatla S. Combination cancer therapy. WO2016016822, 2016.
Ren G, Yi D, Chen J. A crystal form of triazolopyrazine derivative and preparation method. CN105503906, 2016.
Ren G, Yi D, Chen J. B crystal form of savolitinib. CN105503905, 2016.
Yu J, Hao Y, Zhang J, et al. Salt of quinolone compound, polymorphs thereof, preparation method therefor, composition, and applications. WO2017114452, 2017.
Yu J, Guo L, Zhao F, et al. Quinoline-series compound, its preparation method, and pharmaceutical application. CN104109166, 2014.
Wu B, Shao S, Liu J. Compound containing the pharmaceutical composition and its application. CN108276418, 2018.
Guo Y, Peng X, Ji Y, et al. Synthesis of triazolotriazine derivatives as c-Met inhibitors. Mol Divers 2020.
[] [PMID: 32157572]
Kim SC, Boggu PR, Yu HN, et al. Synthesis and biological evaluation of quinoxaline derivatives as specific c-Met kinase inhibitors. Bioorg Med Chem Lett 2020; 30(13): 127189.
[] [PMID: 32371098]
Liang JW, Li SL, Wang S, Li WQ, Meng FH. Synthesis and biological evaluation of novel (E)-N′-benzylidene hydrazides as novel c-Met inhibitors through fragment based virtual screening. J Enzyme Inhib Med Chem 2020; 35(1): 468-77.
[] [PMID: 31902266]
Frigault MM. Use of c-Met inhibitors to treat cancers harbouring met mutations. WO2018055029, 2018.
Shim SH, Lee J, Jung SY, et al. Combination therapy of c-Met-associated cancers using c-Met inhibitors and IGF-1 receptor inhibitors. US20160144027, 2016.
Aftab DT, Lamb P. Drug combinations to treat multiple myeloma. WO2016022697, 2016.
Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem Funct 2019; 37(1): 21-30.
[] [PMID: 30604499]
Sun ZG, Yang YA, Zhang ZG, Zhu HL. Optimization techniques for novel c-Met kinase inhibitors. Expert Opin Drug Discov 2019; 14(1): 59-69.
[] [PMID: 30518273]
Xu H, Wang M, Wu F, Zhuo L, Huang W, She N. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. Bioorg Med Chem 2020; 28(12): 115555.
[] [PMID: 32503697]
Zhang B, Liu X, Xiong H, Zhang Q, Sun X, Yang Z, et al. Discovery of [1,2,4]triazolo[4,3-a]pyrazine derivatives bearing 4-oxo-pyridazinone moiety as potential c-Met kinase inhibitors. New J Chem 2020; 21.
Tang Q, Wang L, Tu Y, et al. Discovery of novel pyrrolo[2,3-b]pyridine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Bioorg Med Chem Lett 2016; 26(7): 1680-4.
[] [PMID: 26923692]
Liu J, Gong Y, Shi J, et al. Design, synthesis and biological evaluation of novel N-[4-(2-fluorophenoxy)pyridin-2-yl]cyclopropanecarboxamide derivatives as potential c-Met kinase inhibitors. Eur J Med Chem 2020; 194: 112244.
[] [PMID: 32224380]
Fan Y, Ding H, Kim D, et al. Antitumor activity of DFX117 by dual inhibition of c-Met and PI3Ka in non-small cell lung cancer. Cancers (Basel) 2019; 11(5): 627.
Lv PC, Yang YS, Wang ZC. Recent progress in the development of small molecule c-Met inhibitors. Curr Top Med Chem 2019; 19(15): 1276-88.
[] [PMID: 31526339]
Zhang Z, Chen Y, Wu H, et al. Design, synthesis, and biological evaluation of novel 2-amino-4-phenylthiazole derivatives as c-Met inhibitors. Youji Huaxue 2018; 38(10): 2648-56.

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy